US2023012463A1PendingUtilityA1

Cyclic sulfamide compounds and methods of using same

Assignee: ASSEMBLY BIOSCIENCES INCPriority: Mar 2, 2017Filed: Jan 14, 2021Published: Jan 12, 2023
Est. expiryMar 2, 2037(~10.6 yrs left)· nominal 20-yr term from priority
C07D 417/04C07D 417/14A61P 31/12C07D 417/10C07D 285/16A61P 31/20A61K 31/549
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present disclosure provides, in part, cyclic sulfamide compounds, and pharmaceutical compositions thereof, useful as modulators of Hepatitis B (HBV) core protein, and methods of treating Hepatitis B (HBV) infection.

Claims

exact text as granted — not AI-modified
1 .- 24 . (canceled) 
     
     
         25 . A compound: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         26 . A pharmaceutical composition comprising a compound: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipient. 
     
     
         27 . A method of treating HBV infection in a subject in need thereof, comprising administering to the subject a compound: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof.

Join the waitlist — get patent alerts

Track US2023012463A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.